Amber Stoll, PA
Medical · Roswell, NMNPI 1598065484
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $422 of the $576 with a category attached, or 73.3%. 8 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 32.8% of the total. Reporting peaked in 2023 at $304 and has fallen 62.7% since, to $114 in 2025.
Across 23 payments — averaging $25.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$189
- Incyte Corporation$134
- Johnson & Johnson$124
- Lilly USA, LLC$61
- Novartis$23
- Regeneron Healthcare Solutions, Inc.$17
- plus $29 from 2 others
What the payments were for
- Food & beverage$42273%
- Education$15427%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 8 | $189 |
| Incyte Corporation | 4 | $134 |
| Johnson & Johnson | 4 | $124 |
| Lilly USA, LLC | 3 | $61 |
| Novartis | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Galderma Laboratories, L.p. | 1 | $15 |
| AbbVie | 1 | $14 |
How this compares
$576 in reported general payments places this provider in the 65th percentile of 156 medical providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 12 | $76,687 |
| Ketoconazole | 289 | $6,634 |
| Fluorouracil | 73 | $5,394 |
| Tacrolimus | 29 | $4,429 |
| Clobetasol Propionate | 81 | $3,301 |
| Calcipotriene | 13 | $2,195 |
| Mometasone Furoate | 95 | $1,921 |
| Ammonium Lactate | 95 | $1,875 |
| Betamethasone Dipropionate | 42 | $1,771 |
| Ciclopirox | 58 | $1,199 |
| Metronidazole | 24 | $1,160 |
| Doxycycline Monohydrate | 46 | $821 |
| Mupirocin | 88 | $784 |
| Imiquimod | 24 | $494 |
| Minoxidil | 72 | $453 |
Paid to pharmacies, not to this prescriber.
Other medical in Roswell
- Sarah East BrumanaRoswell$5K
- Dawn KorfRoswell$3K
- Brenda PachecoAcoma$12K
- Paul TapiaAlbuquerque$7K
- Niki NinopoulosAlbuquerque$7K
- William BaconSanta Fe$6K
- Katie JoshiAlbuquerque$6K
- Loretta GonzalesAlbuquerque$5K
- Ruben FrancoAlbuquerque$4K
- Bradford GwytherAlbuquerque$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.